Skip to main content
FEEDBACK PLC logo

FEEDBACK PLC — Investor Relations & Filings

Ticker · FDBK ISIN · GB00BJN59X09 LEI · 213800UGOF2GT2U2RV90 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2020-04-27 Regulatory Filings
Country GB United Kingdom
Listing IL FDBK

About FEEDBACK PLC

https://fbkmed.com/

Feedback PLC is a medical technology company specializing in clinical infrastructure software designed to improve healthcare communication and workflows. Its flagship product, Bleepa®, is a secure digital platform that enables asynchronous collaboration among clinicians. Bleepa provides a unified, patient-centric view of clinical data, including diagnostic-quality medical imaging, test results, and case notes. The platform facilitates secure messaging and virtual discussions for individuals and multi-disciplinary teams (MDTs), allowing for faster decision-making and streamlined referral pathways. By enabling remote and asynchronous case reviews, Bleepa aims to improve care coordination, reduce outpatient appointment requirements, and shorten patient treatment times across public and private healthcare settings.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1371 characters) and is explicitly labeled as an 'RNS Number'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange, which is a general regulatory market announcement. It does not contain detailed financial results (ER, IR, 10-K) or specific corporate actions like dividends or management changes. Since it is a general regulatory announcement that doesn't fit the highly specific categories like DIV, MANG, or ER, the most appropriate fallback category is Regulatory Filings (RNS).
2020-04-27 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1354 characters) and explicitly states it is providing 'Additional information' via an 'RNS Number'. The content discusses a 'Price Monitoring Extension' related to trading on the London Stock Exchange and mentions that the information is provided by RNS, the news service of the London Stock Exchange, approved by the FCA. This structure—a brief announcement about a market mechanism event disseminated through the official regulatory news service—fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K, IR, ER) or a corporate action announcement (like DIV, SHA, DIRS). It is a general regulatory notification.
2020-04-27 English
Grant of Options
Director's Dealing Classification · 1% confidence The document is identified by the header 'RNS Number : 7179K' and contains detailed information regarding the 'Grant of Options' to directors and employees (Persons Discharging Managerial Responsibilities - PDMRs). It explicitly mentions compliance with the 'EU Market Abuse Regulation' and includes FCA notifications regarding transactions by PDMRs. This type of mandatory disclosure concerning insider transactions (specifically option grants to directors/executives) falls under the category of Director's Dealing (DIRS) or, more broadly, a regulatory announcement. Since the core content is the disclosure of transactions by directors/PDMRs, 'DIRS' is the most specific fit. However, the document is clearly formatted as a general regulatory news service release ('RNS Number', 'This information is provided by RNS...'). Given the options, while it details director transactions, it is fundamentally a regulatory filing disseminated via RNS. Since 'DIRS' specifically covers 'Report of personal share transactions by company directors and executives (insider trades)', and this document details option grants to directors, DIRS is the most precise classification for the *content*. If the content were purely administrative about the RNS release itself, RNS would be better, but the substance is director dealing/remuneration related. Comparing DIRS and DEF 14A (Remuneration), DIRS is better for specific transaction reports. I will classify it as DIRS due to the detailed transaction tables for PDMRs.
2020-04-24 English
Bleepa rolled out at PAH NHS Trust for Covid-19
Environmental & Social Information Classification · 1% confidence The document begins with 'RNS Number : 1183K' and contains information deemed 'inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR")'. It is a press release announcing a business development (roll-out of Bleepa® to an NHS Trust) dated April 20, 2020. This format, including the RNS number and the concluding section referencing RNS and the London Stock Exchange, strongly indicates a general regulatory announcement that does not fit the more specific categories like 10-K, ER, or DIV. Therefore, it should be classified as a Regulatory Filing (RNS).
2020-04-20 English
Feedback Medical to offer Bleepa for COVID-19
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated March 26, 2020. It contains a headline announcing a business development ('Feedback Medical to offer Bleepa to assist Coronavirus response') and includes bullet points summarizing the news. The content is a formal announcement regarding the company's operational response to the COVID-19 pandemic, specifically concerning its Bleepa product. The presence of the RNS Number and the concluding boilerplate text referencing RNS, the London Stock Exchange, and the Financial Conduct Authority strongly indicates this is a regulatory news service announcement. Since it is a general operational/business update that doesn't fit specific categories like Director's Dealing (DIRS), Earnings Release (ER), or Capital Change (CAP), the most appropriate classification is the general regulatory filing category.
2020-03-26 English
Interim Results
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Results for the six months to 30 November 2019' and contains detailed financial summaries, operational highlights, and management commentary for a period shorter than a full fiscal year. It provides substantive financial data (revenue, loss after tax, cash position) and analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2019
2020-02-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.